Novel drug approvals by month

FDA approval dates through September 28

Jan1
Feb4
Mar5
Apr2
May8
Jun3
Jul6
Aug7
Sep9
Year-to-date CDER novel-drug list, not all FDA drug actions.

The Food and Drug Administration's year-to-date list reached 45 novel drug approvals through September 28, 2026. Nine carried September approval dates, the highest monthly count in the first nine months of the year.

“Novel” has a specific scope. FDA uses the page for new molecular entities and new therapeutic biological products whose active ingredients had not previously been approved or marketed in the United States. It is not a count of every new indication, formulation, generic, biosimilar, vaccine, or device action.

Quick read

  • Monthly counts ranged from one approval in January to nine in September.
  • May had eight, August seven, and July six; month-to-month timing does not measure review quality or therapeutic value.
  • The list is year-to-date and can change. Product-specific claims should be checked against approval letters and labeling in Drugs@FDA.

A busy late-summer stretch

FDA's list shows 23 approvals from January through June. July through September contained 22: six in July, seven in August, and nine in September.

That clustering is descriptive. Approval dates can reflect application timing, statutory review clocks, sponsor submissions, agency workload, and when deficiencies are resolved. A monthly count does not say that one month's medicines are more innovative or clinically important than another's.

What the total includes

Each row names a drug, active ingredient, approval date, and the FDA-approved use on that date. The list spans different therapeutic areas and product types. A count treats each row equally even though patient populations, evidence packages, review pathways, and expected use differ.

The approved-use summary is not a substitute for labeling. Indications can include biomarker, age, prior-treatment, or combination-therapy conditions that a short line cannot fully express.

What the total excludes

FDA approves many important changes that are not “novel drug approvals”: a previously approved medicine can gain a new indication, dosage form, age group, or route; a first generic can introduce competition; a biosimilar or vaccine may follow another center's pathway.

The 45 therefore should not be described as all drugs approved in 2026. It is the CDER novel-drug list through the stated cutoff.

A better way to follow approvals

For industry analysis, the list is a starting index. The next step is the application record in Drugs@FDA, where approval letters, labeling, reviews, and application history can establish the exact action. Comparisons over time should use complete calendar years and consistent definitions.

For clinical decisions, labeling and professional guidance—not a release count—govern.

Methodology and limitations

MedDataUSA saved the FDA Novel Drug Approvals for 2026 page on October 7, parsed all rows in the official table, and checked that the displayed sequence number equaled the 45 extracted entries. Monthly counts use the approval date printed by FDA. The latest date in the captured table was September 28.

The page is year-to-date, may be corrected, and is not a complete inventory of FDA actions. We did not classify therapeutic areas, review pathways, orphan status, trial evidence, or commercial impact because those fields require application-level review.

Sources